ada dm guidelines 2021 Algorithm aace glycemic endocrinology glp1 easd hyperglycemia
The management of diabetes has come a long way over the years, and there are now a variety of approaches to glycemic treatment for individuals with the condition. The American Diabetes Association (ADA) provides guidelines for pharmacologic treatment of glycemia in type 2 diabetes, which may involve the use of multiple medications in a combination therapy approach.
Pharmacologic Approaches to Glycemic Treatment
The ADA recommends a stepwise approach to pharmacologic treatment, which involves starting with a single medication and then adding additional medications as needed to achieve patient-specific glycemic goals. The medications used in treatment may vary based on patient factors such as age, comorbidities, and medication adherence.
Some of the recommended medications for glycemic treatment include:
- Metformin: A commonly used first-line medication that works by decreasing the amount of glucose produced by the liver and improving insulin sensitivity
- SGLT2 inhibitors: Medications that work by blocking the reabsorption of glucose in the kidneys, leading to increased glucose excretion and reduced blood glucose levels
- DPP-4 inhibitors: Medications that work by increasing the levels of incretin hormones, which stimulate insulin secretion and decrease glucagon secretion
Early Combination Therapy
While a stepwise approach to pharmacologic treatment is recommended by the ADA, recent research suggests that early combination therapy may be a beneficial approach for some individuals with type 2 diabetes. Early combination therapy involves the use of two or more medications in combination from the start of treatment, rather than introducing additional medications as needed.
A study published in the Lancet found that early combination therapy with metformin and a DPP-4 inhibitor or a SGLT2 inhibitor resulted in better glycemic control and weight loss compared to stepwise therapy with metformin alone. This approach may be particularly beneficial for individuals with higher baseline HbA1c levels or those at higher risk for complications such as cardiovascular disease or diabetic kidney disease.
In conclusion, pharmacologic approaches to glycemic treatment for type 2 diabetes involve a variety of medications that can be used in a stepwise approach or, for some individuals, early combination therapy. A personalized approach to treatment is recommended based on patient factors and glycemic goals, and regular monitoring and reevaluation of treatment is necessary to ensure optimal glycemic control.
If you are searching about Hospitalist ~なんでも無い科医の勉強ノート~: SGLT-2阻害薬は第二選択にせねばならないのか？ you’ve visit to the right web. We have 5 Images about Hospitalist ~なんでも無い科医の勉強ノート~: SGLT-2阻害薬は第二選択にせねばならないのか？ like Early Combination Therapy for Type 2 Diabetes. ADA Guideline, Thread by @DavidACohen_MD: “1/15 For my first , I will start with a and also Early Combination Therapy for Type 2 Diabetes. ADA Guideline. Read more:
Hospitalist ~なんでも無い科医の勉強ノート~: SGLT-2阻害薬は第二選択にせねばならないのか？
hospitalist-gim.blogspot.comEarly Combination Therapy For Type 2 Diabetes. ADA Guideline
www.diabetesasia.orgguideline consenso tratar adultos escolher diabetesasia
Thread By @DavidACohen_MD: “1/15 For My First , I Will Start With A
threadreaderapp.comada diabetes care standards medical medication updated treatment algorithm management medications sglt2 releases approach cardiovascular
Comparison Of The Diabetes Guidelines From The ADA/EASD And The AACE
www.japha.orgalgorithm aace glycemic endocrinology glp1 easd hyperglycemia
- Pharmacologic Approaches To Glycemic Treatment: Standards Of Medical
care.diabetesjournals.orgstandards glycemic approaches consenso adultos tratar insulina pharmacologic
Early combination therapy for type 2 diabetes. ada guideline. 9. pharmacologic approaches to glycemic treatment: standards of medical. Algorithm aace glycemic endocrinology glp1 easd hyperglycemia